THE NEUTRAL ZONE
Remdesivir, a drug originally developed to treat Ebola, showed positive results for treatment of COVID-19 in a recent government study, the National Institute of Allergy and Infectious Diseases announced Wednesday. The data showed recovery time decreased by 31% with remdesivir treatment as compared to the placebo treatment. While more data is needed for a decisive conclusion, the results are the first to show positive results from possible remedies.
The Food and Drug Administration is likely to fast-track approval of the drug for emergency use in the coming days. Dr. Anthony Fauci lauded the outcome of the trial while warning the drug is not a “knockout.”
Despite the positive outcome of the NIAID study, not all are convinced of remdesivir’s efficacy. A double-blind trial in 10 hospitals in Hubei, China, found no “statistically significant clinical benefits.” The study was published in The Lancet medical journal on the same day the NIAID results were announced.
Coronavirus Treatment: Fauci Says Remdesivir Has ‘Clear-Cut, Significant Positive Effect’ On Patients – International Business Times – 4/29/2020
Speaking from the White House, Dr. Fauci declared remdesivir can block “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),” the virus that causes COVID-19. More important from a patient’s standpoint is remdesivir shortened the period patients experienced symptoms and slightly reduced the mortality rate.
Gilead will ramp up remdesivir production — but it can only go so fast – STAT – 4/30/2020
A study run by the National Institute of Allergy and Infectious Diseases showed that patients with Covid-19 who were given the drug recovered faster than those who were given a placebo, the agency said this week. Regulators have not yet approved the drug — though an emergency authorization is reportedly imminent — but the company now stands in the position of having to scale up production of a drug that the whole world may want.
Is remdesivir a miracle drug to cure coronavirus? Don’t get your hopes up yet – The Conversation – 4/30/2020This showed COVID-19 patients recovered more quickly and had an improved survival rate when taking the drug, compared with those given a placebo and standard care. But these are just the preliminary results of one study. Other human trials have not shown similar results.
Why some experts want more data before they are convinced about remdesivir – ThePrint – 4/30/2020
While Anthony Fauci, the National Institute for Allergy and Infectious Diseases director, said a U.S. government-run trial met its overall target, full details haven’t been published. At the same time, the only large, rigorous study for which full data is public — a Chinese trial published in The Lancet medical journal on Wednesday — showed the opposite.
Andrew Yang🧢🇺🇸 @Andrew Yang🧢🇺🇸 30 Apr https://t.co/To42mRJcQX Remdesivir has documented positive effects on recovery time
Marco Rubio @Marco Rubio 29 Apr If Remdesivir proves to accelerate recovery from #COVID__19 it would represent a major & positive development Diminishing the virus’s impact could protect our health systems capacity & therefore provide some additional flexibility in our re-openinghttps://t.co/YuPevT6D0N
Sarah Owermohle @Sarah Owermohle 30 Apr Lancet lifts its embargo on negative remdesivir data after Gilead promised positive results were incoming this morning https://t.co/08nE5XTpQv… https://t.co/uGTslx0qbb
André Picard @André Picard 30 Apr Mixed results on #Remdesivir. Gilead claims ‘positive data’ coming. Another study reports the drug offers no benefit to severely ill patients, by @ginakolata https://t.co/F3h3j795WW via @nytimes #COVID19
#TestAndTrace EVERYWHERE NOW 🐇 @#TestAndTrace EVERYWHERE NOW 🐇 30 Apr Some positive news for Remdesivir, though the effect size is pretty small. https://t.co/vbUvcRRJYa